Brazil's NSCLC cancer drug market will reach $240 million by 2014, new study shows

8 July 2010

The non-small-cell lung cancer (NSCLC) drug market in Brazil will reach a value $240 million by 2014, according to a new report from advisory firm Decision Resources. Factors fueling this growth include a slight but steady annual increase in the number of incident cases, greater uptake of higher-priced brands of chemotherapy, targeted regimens and maintenance treatment (all in the advanced setting) and modest uptake of novel targeted agents.

"Through the Brazilian national health system, virtually all diagnosed patients have access to treatment. However, a small but lucrative segment of patients with private health insurance largely drives the use of premium-priced novel chemotherapy and targeted agents," stated Decision Resources' analyst Janie Cox.

Dominated by Roche and Lilly drugs

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK